Chronic Myeloid Leukemia

ISBN-13: 9783030719128 / Angielski / Twarda / 2021 / 273 str.

Rüdiger Hehlmann

Spis treści

1. Cytogenetics of Chronic Myeloid Leukemia (CML)
2. The Biology and Pathogenesis of Chronic Myeloid Leukaemia
3. Epidemiology of Chronic Myeloid Leukemia
4. Imatinib and the first line CML Therapy
5. CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors
Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
6. Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
7. Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update
8. Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death
9. A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
10. The Role of Hematopoietic Stem Cell Transplantation in CML
11. CML end-phase and blast crisis: implications and management
12. The Interferon-alpha Revival in CML
13. Managing Pregnancy in Chronic Myeloid Leukemia
14. Response-Related Predictors of Survival and of Treatment Free Remission in CML
15. Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response 

O autorze

Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany.

Founder and Chair, European LeukemiaNet (ELN)

Founder and chair of the German CML Study Group 1982-2017

Former Secretary General

International Association of Comparative Research on Leukemia & Related Diseases (IACRLRD)

Former Chief of Medicine, Dean & President

German Society of Hematology and Oncology

Honorary member of the Polish and German Societies for Hematology and Oncology

Current focus: promotion of cooperative research for curing leukemia

Blurb

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.